When the variation applies

Use the limited-capacity pathway when the person cannot understand, retain, weigh, or communicate the information needed for trial consent despite suitable support. The protocol and recruitment procedure should explain how capacity is assessed, who assesses it, when it is reassessed, and how fluctuating or temporary incapacity is handled.

Article 31 also requires a trial involving an incapacitated participant to meet strict conditions, including scientific necessity, minimal risk and burden unless direct benefit justifies more, and either a prospect of direct benefit or the limited group-benefit route defined in the Regulation. No incentives may be offered to the participant or representative beyond reimbursement of expenses and loss of earnings directly related to participation.

Latvia decision-makers

For a patient unable to express their wishes and not under a relevant court arrangement, the Latvian Law on the Rights of Patients identifies the patient's authorised person, spouse, partner, or closest relative as possible decision-makers. Written consent is required, and the patient must not previously have objected to trial participation.

If the patient is under guardianship or trusteeship, written consent is given by the lawful representative, or by the guardian together with the patient according to the court-defined restriction on legal capacity. The site should verify and record the decision-maker's authority before consent.

The law contains detailed rules for medical-treatment decisions when several relatives are available. Confirm the lawful person for the individual case rather than copying a generic hierarchy into the consent form. If authority is uncertain, do not enroll until it is resolved.

Documents to prepare

Mandatory. Legal-representative information and consent. Provide a Latvian document explaining why the participant cannot consent, the trial, expected benefit, risks, burden, alternatives, data, samples, compensation, insurance, withdrawal, and the representative's role. Include separate fields for the participant and representative identity and authority.

Mandatory. Participant information. Give the participant information in a form and language suited to their ability. This may be a simplified Latvian sheet, visual aid, supported discussion, or another approved format. State how assent, wishes, and objections are assessed and recorded.

Conditional. Capacity-assessment or emergency materials. Include an approved process or form when the protocol uses a structured assessment. If incapacity arises in an urgent life-threatening situation and prior representative consent cannot be obtained, the separate Article 35 route applies. See the Latvia emergency enrollment consent guide.

The blank documents are not signed at submission. At enrollment, the lawful decision-maker and the person conducting the consent interview sign and date the consent. The participant signs only to the extent appropriate and legally meaningful for their capacity and the approved form.

Objection, withdrawal, and regained capacity

Respect the explicit wish of a participant who can form an opinion and assess the information to refuse participation or withdraw. A representative cannot override that research objection. Document non-verbal as well as verbal resistance where it may express a wish.

The participant or the person who consented may end participation at any time without adverse effects on later medical care. Explain which safety follow-up remains advisable and how lawfully collected data and mandatory records are handled.

If the participant regains capacity, provide the current adult Latvian information and obtain their own written consent for continued participation as soon as possible. Revisit optional data and sample choices with the participant. The representative's earlier consent does not replace the participant's later decision.

Complete the Latvia patient-facing document QC checklist and return to the Latvia CTIS guide hub for the other consent variations.

Prepare the representative package in minutes

TrialAgents can generate the complete Latvia limited-capacity consent and CTIS Part II package in minutes, saving weeks of manual drafting and pathway alignment.

Official sources and resources

  1. Law on the Rights of Patients, Sections 7 and 11, official English translation.
  2. Regulation (EU) No 536/2014 on Clinical Trials, Articles 29 and 31, consolidated text of 5 December 2022.
  3. Cabinet Regulation No. 192, Clinical Trials of Medicinal Products for Human Use, paragraphs 28 to 34, adopted 26 March 2024.
  4. Overview Part II Requirements in a Clinical Trial Application, Latvian Local Requirements, version 2.0, 4 February 2025.

Last reviewed: 31 August 2026